Results 91 to 100 of about 14,520 (202)

Abstract P4-04-17: Elacestrant (RAD1901) demonstrates anti-tumor activity in a fulvestrant-resistant PDX model

, 2018
Background: Breast cancer is subdivided into categories based on tumor receptor status, with estrogen-receptor positive (ER+) breast cancer making up approximately two-thirds of all breast cancers diagnosed.
F Garner, T Bihani, H Arlt
core   +1 more source

Capivasertib/Fulvestrant in patients with HR+, HER2-low or HER2-negative locally advanced or metastatic breast cancer

Therapeutic Advances in Medical Oncology
The landscape of breast cancer treatment continues to evolve. Survival rates have improved due to advancements in treatments such as endocrine therapy, cyclin-dependent kinase 4/6 inhibitors and targeted therapies.
Karam Aboud, Magda Meissner, Rob Jones
doaj   +1 more source

Fulvestrant and male breast cancer: a pooled analysis

, 2015
Male breast cancer is an uncommon malignancy; little is known regarding hormonal manipulations for tamoxifen-resistant male breast cancer patients. This is the first pooled analysis of the literature to synthesize all available data and to evaluate the ...
Chrysikos, D., Sergentanis, T.N., Sergentanis, Theodoros N, Dimopoulos, M.-A., Zagouri, Flora, Chrysikos, Dimosthenis, Psaltopoulou, Theodora, Psaltopoulou, T., Dimopoulos, Meletios-Athanasios, Zagouri, F.   +9 more
core  

Everolimus Enhances the Efficacy of Fulvestrant in ER+ Breast Cancer

, 2018
mTOR inhibition with everolimus extends progression-free survival in combination with fulvestrant.

core   +1 more source

Advances of fulvestrant in treatment of advanced breast cancer in hormone receptor-positive postmenopausal women

Zhongguo aizheng zazhi, 2016
Endocrine therapy targeting estrogen pathway is one of the first-line treatment choices of advanced breast cancer. Fulvestrant is a pure estrogen antagonist that blocks and downgrades estrogen receptor, which makes it effective in the treatment of ...
王佳玉, 徐兵河
doaj  

Identification of fulvestrant analogues for estrogen receptor alpha binding in breast cancer using molecular docking and molecular dynamics simulation

Discover Chemistry
Breast cancer remains a major global health challenge, with approximately 80% of cases classified as estrogen receptor-positive (ER+). Fulvestrant, a steroidal antiestrogen and selective estrogen receptor degrader (SERD), is widely used in ER+ breast ...
Atharva Balpande, Anushka Dashputra, Nikhil Khanwani, Yashasvi Therkar, Aryan Wasewar, Ganesh C. Patil, C. Ravikumar   +6 more
doaj   +1 more source

Fulvestrant in treatment for metastatic breast cancer

, 2019
Background. Metastatic breast cancer is still an incurable disease, and is currently regarded as a chronic process requiring longterm treatment with periodic therapy replacements.
A. A. L’yanova, N. M. Tikhanovskaya, K. A. Novoselova, M. A. Teplyakova, N. A. Abramova, A. E. Storozhakova, L. A. Ryadinskaya, L. Yu. Vladimirova, I. L. Popova, L. K. Strakhov, M. O. Ezhova   +10 more
core   +1 more source

Response to fulvestrant in heavily pretreated postmenopausal women:a single-center experience

, 2004
Fulvestrant (`Faslodex') is a new estrogen receptor (ER) antagonist that has no agonist effects. It binds, blocks and accelerates degradation of the ER, leading to a complete abrogation of estrogen-sensitive gene transcription.
Tan-chiu, Elizabeth, Frankel, Cynthia, Franco, Sandra, Perez, Alejandra, Vogel, Charles   +4 more
core   +1 more source

Preclinical and clinical experience with fulvestrant (Faslodex) in postmenopausal women with hormone receptor-positive advanced breast cancer

, 2005
Fulvestrant (Faslodex) is a new type of estrogen receptor (ER) antagonist that binds, blocks, and degrades the ER, leading to reduced expression of the progesterone receptor (PgR). Unlike the selective ER modulator tamoxifen, fulvestrant is devoid of any
Bundred, Nigel
core   +1 more source

Genome-wide shRNA screening identifies genes involved in fulvestrant resistance in breast cancer [PDF]

, 2016
Breast cancer accounts as the most prevalent cancer and the leading cause of cancer death worldwide among women. Estrogen is one main factor responsible for tumour growth in breast cancer patients through stimulation of estrogen receptor (ER) signalling.
Ramos, Pedro André Dias
core